This article is more than 5 years old. Information may no longer be current.

Panel rules in favor of InSite in patent interference litigation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ALAMEDA, Calif. — The U.S. Patent and Trademark Office ruled in favor of InSite Vision regarding its patent interference litigation with the University of California, San Francisco, the company announced in a press release.

The university in 2009 said the inventions in U.S. patent Nos. 6,239,113 and 6,569,443 - those protecting AzaSite (azithromycin 1% ophthalmic solution) - were made entirely by a former university employee with no input from InSite, according to the release.

But a panel of Patent and Trademark Office judges ruled in favor of InSite.

"We are extremely pleased that the [U.S. Patent and Trademark Office] has concurred with our long-held position in this case," Timothy Ruane, InSite's CEO, said in the release. "We now turn our full attention to maximizing the continued commercial success of AzaSite in the marketplace and to advancing our clinical trial programs, including those within the AzaSite franchise."